Form D · Other
Impact Genomics, Inc.
La Jolla, CA · CIK 0001690870
Offering snapshot reported Jan 30, 2017 · SEC filing
- Reported sold
- $10.2M Offering amount: $10.2M
- Investors reported
- 32 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 23, 2016 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$9,339,988 → $10,215,947
- Reported investors20 → 32
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 30, 2017 | Amendment | $10,215,947 | $875,959vs Dec 7, 2016 | 32 | SEC filing |
| Dec 7, 2016 | Amendment | $9,339,988 | $0vs Dec 7, 2016 | 20 | SEC filing |
| Dec 7, 2016 | Initial | $9,339,988 | No comparison | 20 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-275823
$224,996.79 cancellation of indebtedness, that is designated Series A-1 stock; $9,990,948.13 new-cash, that is designated Series A stock
Source: Form D, filed Jan 30, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Samuel Levy | Director, Executive |
| Kenneth Nesmith | Director, Executive |
| John Spinosa | Director, Executive |
Issuer details
Industry: Other (See others in industry)
Address:
2645 Ridgegate Road
La Jolla, CA, 92037
La Jolla, CA, 92037